RSC Advances



RETRACTION

View Article Online
View Journal | View Issue



Cite this: RSC Adv., 2025, 15, 947

Retraction: Yiqi Fumai lyophilized injection attenuates doxorubicin-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats by inhibition of oxidative stress, inflammation and apoptosis

Yue Gu,^a Aichun Ju,^b Bingjie Jiang,^a Jingze Zhang,^{*c} Shuli Man,^{*d} Changxiao Liu†^e and Wenyuan Gao^{*a}

DOI: 10.1039/d5ra90003d

rsc.li/rsc-advances

Retraction of 'Yiqi Fumai lyophilized injection attenuates doxorubicin-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats by inhibition of oxidative stress, inflammation and apoptosis' by Yue Gu *et al.*, *RSC Adv.*, 2018, **8**, 40894–40911, https://doi.org/10.1039/C8RA07163B.

The Royal Society of Chemistry, with the agreement of the authors below, hereby wholly retracts this RSC Advances article due to concerns with the reliability of the data.

There are several duplications of image panels within this paper with images published in other papers by different authors; Fig. 7C YQFM/TGF- β 1 panel with ref. 1, Fig 11C YQFM/Liver with ref. 2, Fig 11B Control/Liver with ref. 3, Fig 11C DOX/Liver with ref. 3, Fig 11B YQFM/Heart with ref. 4 and Fig 11F western blot GADPH band with ref. 5.

Within the paper, there are many duplications including the Fig. 10A DOX/Kidney (COX-2) panel with the Fig. 11D DOX/Kidney (Cytochrome C) panel, the Fig. 11A DOX + YQFM/Heart (BAX) panel with the Fig. 11B DOX + YQFM/Heart (BCl-2) panel, and the BCl-2 western blot bands within Fig. 11F and G.

The authors state that they obtained the images in Fig. 7C, 8A-L, 10A, 11A-G and 12A-L from a third party.

Given the significance of these concerns, the Editor has lost confidence that the findings presented in this paper are reliable. Signed: Yue Gu, Bingjie Jiang, Shuli Man, Aichun Ju, Jingze Zhang, Wenyuan Gao

Date: 17th December 2024

Retraction endorsed by Laura Fisher, Executive Editor, RSC Advances

References

- 1 Y. Li, T. Xia, R. Li, G. Tse, T. Liu and G. Li, Med. Sci. Monit., 2019, 25, 1582–1589.
- 2 X.-B. Zheng, X.-B. Chen, L.-L. Xu, M. Zhang, L. Feng, P.-S. Yi, J.-W. Tang and M.-Q. Xu, Cancer Sci., 2017, 108, 338-346.
- 3 J.-J. Liu, Y. Xu, S. Chen, C.-F. Hao, J. Liang and Z.-L. Li, World J. Gastroenterol., 2022, 28, 4635-4648.
- 4 N. Cheng, C. Jin, P. Jin, D. Zhu and Z. Hou, J. Cell. Mol. Med., 2021, 25, 6137, DOI: 10.1111/jcmm.16527.
- 5 Z. Zhuang, D. Yu, Z. Chen, D. Liu, G. Yuan, N. Yirong, L. Sun, Y. Liu, R. He and K. Wang, *J. Evidence-Based Complementary Altern. Med.*, 2019, 2019, 1–12.

[&]quot;Tianjin Key Laboratory for Modern Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Weijin Road, Tianjin 300072, China. E-mail: pharmgao@tju.edu.cn; Fax: +86-22-87401895; Tel: +86-22-87401895

^bTasly Pride Pharmaceutical Company Limited, Tianjin 300410, China

Department of Pharmacy, Logistics University of Chinese People's Armed Police Forces, Tianjin 300309, China. E-mail: zhangjingze1877@163.com; Tel: +86-22-84876773

dState Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, China. E-mail: msl@tust.edu.cn; Tel: +86-22-6661265

eThe State Key Laboratories of Pharmacodynamics and Pharmacokinetics, Tianjin 300193, China

[†] Deceased.